Bioxcel Therapeutics Stock Current Valuation
| BTAI Stock | USD 0.33 0.01 1.88% |
Valuation analysis of BioXcel Therapeutics helps investors to measure BioXcel Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -0.7. The current Enterprise Value Multiple is estimated to decrease to -0.7. Fundamental drivers impacting BioXcel Therapeutics' valuation include:
Undervalued
Today
Please note that BioXcel Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of BioXcel Therapeutics is based on 3 months time horizon. Increasing BioXcel Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioXcel Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioXcel Stock. However, BioXcel Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.33 | Real 0.94 | Target 2.81 | Hype 0.36 | Naive 0.33 |
The intrinsic value of BioXcel Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence BioXcel Therapeutics' stock price.
Estimating the potential upside or downside of BioXcel Therapeutics helps investors to forecast how BioXcel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioXcel Therapeutics more accurately as focusing exclusively on BioXcel Therapeutics' fundamentals will not take into account other important factors: BioXcel Therapeutics Company Current Valuation Analysis
BioXcel Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioXcel Therapeutics Current Valuation | 80.96 M |
Most of BioXcel Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioXcel Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioXcel Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for BioXcel Therapeutics is extremely important. It helps to project a fair market value of BioXcel Stock properly, considering its historical fundamentals such as Current Valuation. Since BioXcel Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioXcel Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioXcel Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
BioXcel Current Valuation Historical Pattern
Today, most investors in BioXcel Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioXcel Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioXcel Therapeutics current valuation as a starting point in their analysis.
BioXcel Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioXcel Therapeutics has a Current Valuation of 80.96 M. This is 99.44% lower than that of the Biotechnology sector and 98.26% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.51% higher than that of the company.
BioXcel Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioXcel Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics of similar companies.BioXcel Therapeutics is currently under evaluation in current valuation category among its peers.
BioXcel Fundamentals
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (14.89) % | ||||
| Current Valuation | 80.96 M | ||||
| Shares Outstanding | 49.63 M | ||||
| Shares Owned By Insiders | 20.06 % | ||||
| Shares Owned By Institutions | 8.70 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 6.67 X | ||||
| Revenue | 1.38 M | ||||
| Gross Profit | 1.04 M | ||||
| EBITDA | (165.42 M) | ||||
| Net Income | (179.05 M) | ||||
| Cash And Equivalents | 233.45 M | ||||
| Cash Per Share | 8.33 X | ||||
| Total Debt | 101.38 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 12.25 X | ||||
| Book Value Per Share | (1.89) X | ||||
| Cash Flow From Operations | (155.01 M) | ||||
| Short Ratio | 0.93 X | ||||
| Earnings Per Share | (2.04) X | ||||
| Price To Earnings To Growth | (0.01) X | ||||
| Target Price | 2.31 | ||||
| Number Of Employees | 74 | ||||
| Beta | 0.29 | ||||
| Market Capitalization | 16.03 M | ||||
| Total Asset | 73.7 M | ||||
| Retained Earnings | (590.6 M) | ||||
| Working Capital | 44.88 M | ||||
| Current Asset | 609.37 K | ||||
| Current Liabilities | 1.67 M | ||||
| Net Asset | 73.7 M |
About BioXcel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioXcel Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out BioXcel Therapeutics Piotroski F Score and BioXcel Therapeutics Altman Z Score analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share | Quarterly Revenue Growth 1.416 | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.